Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Prognostic and predictive factors associated with ipilimumab-related adverse events: a retrospective analysis of 11 NCI-sponsored phase I clinical trials

Oncotarget(2020)10.18632/oncotarget.27537Source: DataRank Database

Prognostic and predictive factors associated with ipilimumab-related adverse events: a retrospective analysis of 11 NCI-sponsored phase I clinical trials is a research paper published in Oncotarget (2020). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.00)OA: goldTopics (15)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Tanvir Kabir ORCID,Jianrong Wu ORCID,Jing Wei ORCID,Mary Ann Cook,Charles A. Kunos

Live enrichment

PubMed:32363000 PMC:PMC7185063 OpenAlex:https://openalex.org/W3017664130

NCI NIH HHS

Grant: UM1 CA186712

NCI NIH HHS

Grant: P30 CA177558

FWCI

0.00

Citation Percentile

0.0%

goldLicense: cc-by

journalhttps://www.oncotarget.com/article/27537/pdf/

publisherhttps://www.oncotarget.com/article/27537/pdf/

publisherhttps://www.oncotarget.com/lookup/doi/10.18632/oncotarget.27537

journalhttps://doi.org/10.18632/oncotarget.27537

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32363000

Fields of Study

Cancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmunotherapy and Immune Responses

Keywords

IpilimumabMedicineAdverse effectInternal medicineClinical trialOncologyCancerImmunotherapyToxicityMetastatic MelanomaImmune Checkpoint InhibitorsCo-administered Agents